Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Stopped Termination of this study was a business decision made during portfolio review.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Urothelial Cancer
- Poorly Differentiated Neuroendocrine Carcinomas
- Homologous Recombination Deficient-Positive Malignancies Agnostic
Interventions
Sponsor
Jazz Pharmaceuticals
Collaborators